Evidence map›Paper›PMID 41449215›Full record

ReviewVirchows Archiv : an international journal of pathology2026

An update on the role of SMARCA4 deficiency in gynecological neoplasms: how and where.

Livia Maccio, Emma Bragantini, Giuseppe Angelico, Giulia Scaglione, Antonio De Leo, Angela Santoro, Gian Franco Zannoni

Abstract readReview
PubMed Publisher
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Livia Maccio *Department of Pathology, Ospedale San Maurizio, Bolzano, Italy.
Emma Bragantini *Department of Pathology, Ospedale San Maurizio, Bolzano, Italy.
Giuseppe AngelicoDepartment of Medicine and Surgery, Kore University of Enna, Enna, 94100, Italy.
Giulia ScaglionePathology Unit, Department of Woman and Child's Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Ge-Melli 8, Rome, 00168, Italy.
Antonio De LeoDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, 40138, Italy.
Angela SantoroPathology Unit, Department of Woman and Child's Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Ge-Melli 8, Rome, 00168, Italy.
Gian Franco ZannoniPathology Unit, Department of Woman and Child's Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Ge-Melli 8, Rome, 00168, Italy. gianfranco.zannoni@unicatt.it.ORCID http://orcid.org/0000-0002-4473-7560

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SMARCA4, encoding the BRG1 protein, is a crucial component of the SWI/SNF chromatin remodeling complex, essential for regulating gene expression and maintaining genomic integrity; our knowledge regarding the role of these genes continues to evolve. Deficiency or loss of SMARCA4 expression has been implicated in the development and progression of various gynecological neoplasms, notably small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), SMARCA4-deficient uterine sarcoma, and some subtypes of endometrial carcinoma such as undifferentiated or dedifferentiated carcinoma. Given its central role in oncogenesis, targeting SMARCA4-deficient tumors has become an area of active research, with potential therapeutic strategies above all in these aggressive gynecological tumor subtypes. This review summarizes current knowledge of the role of SMARCA4 deficiency in gynecological cancers, discussing the morphological and immunophenotypic characteristics of the different entities, emphasizing clinical implications and potential targeted therapies. Further understanding of its structure, function, and therapeutic vulnerabilities is crucial for improving patient outcomes.

Indexed as

Biomarkers, TumorDNA HelicasesGenital Neoplasms, FemaleNuclear ProteinsTranscription FactorsFemaleHumansBiomarkers, TumorDNA HelicasesNuclear ProteinsSMARCA4 protein, humanTranscription FactorsBRG1Endometrial carcinomaGenetic testingGynecological neoplasmsOvarian cancerRhabdoid Tumor Predisposition Syndrome 2 (RTPS2)SMARCA4SWI/SNF complexUterine sarcoma

Identifiers

PMID41449215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.